AbbVie today announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Structural Health Monitoring Market Size Worth USD 4.3 Billion by 2030 at CAGR of 15% - Report by Market Research Future (MRFR) forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment.
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab) - read this article along with other careers information, tips and advice on BioSpace